http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medi
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
-
Cytokinetics Reports Third Quarter 2020 Financial Results
-
Cytokinetics to Announce Third Quarter Results on November 4, 2020
-
Amgen (AMGN), Cytokinetics (CYTK) And Servier Announce Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Achieved Primary Composite Efficacy Endpoint, No Reduction in Secondary
-
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
-
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cytokinetics (CYTK) Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
-
Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
-
Cytokinetics (CYTK) Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
-
Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
-
Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
-
Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
-
Cytokinetics (CYTK) Begins Phase 1 Clinical Study of CK-3772271
-
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
-
Cytokinetics (CYTK) Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
-
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
-
Cytokinetics to Participate in Upcoming Investor Conferences
-
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
-
Cytokinetics (CYTK) Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
-
Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
-
Cytokinetics Reports Second Quarter 2020 Financial Results
-
Cytokinetics to Announce Second Quarter Results on August 6, 2020
-
Pre-Open Movers 07/16: (LCI) (DELL) (AA) Higher; (TCDA) (NCLH) (GENE) Lower (more...)
-
After-Hours Stock Movers 07/15: (RTIX) (DELL) (AA) Higher; (TCDA) (CYTK) (TWTR) Lower (more...)
-
Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
-
Cytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
-
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
-
Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
-
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
-
Cytokinetics to Participate In Upcoming Investor Conferences
-
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
-
Amgen (AMGN) and Cytokinetics (CYTK) Announce FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
-
FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure
-
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
-
Cytokinetics to Hold Annual Meeting of Stockholders
-
Cytokinetics Reports First Quarter 2020 Financial Results
-
Cytokinetics to Announce First Quarter Results on May 6, 2020
-
Cytokinetics (CYTK) Announces Clinical Trials and Business Update in Response to COVID-19 Pandemic
-
Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
-
Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
-
Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
-
Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
-
CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC
-
Cytokinetics (CYTK) Granted European Orphan Designation for Reldesemtiv for Treatment of Amyotrophic Lateral Sclerosis
-
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
-
Cytokinetics Reports Fourth Quarter 2019 Financial Results
-
Cytokinetics (CYTK) Announces Preclinical Data for AMG 594 Presented at Keystone Symposium on Heart Failure

